Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Wheaton Precious Metals Corp — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Wheaton Precious Metals Corp trades at $133.33 (market cap $61.55B). The key difference: Wheaton Precious Metals Corp is far larger — about 8.2× Spyre Therapeutics Inc. Common Stock's market cap, and Wheaton Precious Metals Corp pays a 0.57% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Wheaton Precious Metals Corp for 66 Days on average.
| SYRE | WPM | |
|---|---|---|
Market Cap | $7.52B | $61.55B |
Volume | 1,441,031 | 932,802 |
Sector | Health | Basic Materials |
52-Week High | $108.92 | $165.72 |
52-Week Low | $22.18 | $94.37 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $6.52B | $63.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Wheaton Precious Metals (WPM) trades at $136.03, down 1.51% on the day, amid a bullish technical setup and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $2.31 billion and net income of $1.47 billion, supported by a 64.66% net margin. Recent news highlights expansion plans targeting 1.2 million ounces by 2030, with a fully funded pipeline driving investor optimism.
The outlook remains positive given analyst consensus of a $164.80 price target and 80% buy ratings. Key risks include execution of growth targets and sensitivity to gold prices, but strong cash flow and institutional interest underpin potential upside for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
